Research programme: retinal disorder therapeutics - Everads Therapy/VivaVision Biotech
Latest Information Update: 03 Feb 2023
At a glance
- Originator Everads Therapy; VivaVision Biotech
- Class Eye disorder therapies; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Eye disorders